NuVasive, Inc. (NUVA) CEO Acquires $291,420.00 in Stock
NuVasive, Inc. (NASDAQ:NUVA) CEO Gregory T. Lucier purchased 6,000 shares of the stock in a transaction on Thursday, March 1st. The shares were purchased at an average cost of $48.57 per share, with a total value of $291,420.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.
Shares of NuVasive, Inc. (NASDAQ:NUVA) traded up $1.37 during mid-day trading on Monday, hitting $49.40. The stock had a trading volume of 474,538 shares, compared to its average volume of 1,062,992. The firm has a market cap of $2,520.00, a PE ratio of 42.59, a PEG ratio of 1.30 and a beta of 0.50. The company has a current ratio of 3.48, a quick ratio of 1.94 and a debt-to-equity ratio of 0.73. NuVasive, Inc. has a fifty-two week low of $44.62 and a fifty-two week high of $81.68.
NuVasive (NASDAQ:NUVA) last issued its quarterly earnings data on Monday, February 26th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.56. The business had revenue of $271.70 million during the quarter, compared to analysts’ expectations of $272.11 million. NuVasive had a return on equity of 13.40% and a net margin of 8.06%. The company’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.53 EPS. research analysts expect that NuVasive, Inc. will post 2.46 EPS for the current year.
A number of analysts have commented on NUVA shares. Royal Bank of Canada lowered their price target on NuVasive from $75.00 to $70.00 and set an “outperform” rating for the company in a research report on Friday, November 10th. BTIG Research set a $74.00 price target on NuVasive and gave the stock a “buy” rating in a research report on Wednesday, December 13th. BMO Capital Markets reaffirmed a “buy” rating and set a $70.00 price target on shares of NuVasive in a research report on Thursday, December 14th. BidaskClub raised NuVasive from a “sell” rating to a “hold” rating in a research report on Friday, December 15th. Finally, Zacks Investment Research raised NuVasive from a “sell” rating to a “hold” rating in a research report on Tuesday, December 19th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $68.19.
ILLEGAL ACTIVITY WARNING: This report was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2018/03/05/nuvasive-inc-nuva-ceo-acquires-291420-00-in-stock.html.
NuVasive Company Profile
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.